Crispr Therapeutics [CRSP] vs Bio-Techne [TECH] Detailed Stock Comparison

Crispr Therapeutics

NASDAQ
Loading...

Bio-Techne

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Crispr Therapeutics wins in 5 metrics, Bio-Techne wins in 12 metrics, with 0 ties. Bio-Techne appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricCrispr TherapeuticsBio-TechneBetter
P/E Ratio (TTM)-15.61136.85Crispr Therapeutics
Price-to-Book Ratio3.505.08Crispr Therapeutics
Debt-to-Equity Ratio12.5923.14Crispr Therapeutics
PEG Ratio-0.26-0.96Bio-Techne
EV/EBITDA-10.6530.42Crispr Therapeutics
Profit Margin (TTM)-215.00%6.02%Bio-Techne
Operating Margin (TTM)-14,918.27%36.30%Bio-Techne
EBITDA Margin (TTM)N/A36.30%N/A
Return on Equity-25.34%3.68%Bio-Techne
Return on Assets (TTM)-13.05%6.30%Bio-Techne
Free Cash Flow (TTM)$-144.68M$256.55MBio-Techne
Dividend YieldN/A0.79%N/A
1-Year Return49.82%-15.59%Crispr Therapeutics
Price-to-Sales Ratio (TTM)161.928.04Bio-Techne
Enterprise Value$4.66B$10.07BBio-Techne
EV/Revenue Ratio122.348.26Bio-Techne
Gross Profit Margin (TTM)N/A62.72%N/A
Revenue per Share (TTM)$0$8Bio-Techne
Earnings per Share (Diluted)$-5.40$0.46Bio-Techne
Beta (Stock Volatility)1.841.48Bio-Techne
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Crispr Therapeutics vs Bio-Techne Stock Performance Analysis

Loading Price Chart...

Crispr Therapeutics
Bio-Techne
Crispr Therapeutics Stock Overview | Bio-Techne Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Crispr Therapeutics3.62%10.07%29.74%37.12%116.77%69.42%
Bio-Techne-1.64%18.55%14.43%20.14%18.37%-13.37%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Crispr Therapeutics49.82%29.81%-36.09%407.89%407.89%407.89%
Bio-Techne-15.59%-12.43%-6.78%160.83%298.20%351.64%

News Based Sentiment: Crispr Therapeutics vs Bio-Techne

Crispr Therapeutics

News based Sentiment: MIXED

October presented a mixed bag for CRISPR Therapeutics, with encouraging sales growth for Casgevy and promising pipeline developments offset by continued financial losses and a challenging earnings outlook. The company is making progress, but significant hurdles remain in achieving profitability and sustained growth.

View Crispr Therapeutics News Sentiment Analysis

Bio-Techne

News based Sentiment: MIXED

Bio-Techne experienced a strong month with significant stock gains fueled by positive earnings and a broader healthcare sector rally. However, analyst concerns regarding organic growth and declining free cash flow create a mixed investment picture, requiring investors to carefully weigh the potential risks and rewards.

View Bio-Techne News Sentiment Analysis

Performance & Financial Health Analysis: Crispr Therapeutics vs Bio-Techne

MetricCRSPTECH
Market Information
Market Cap i$6.24B$9.80B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i2,514,7393,192,556
90 Day Avg. Volume i2,285,1102,630,039
Last Close$70.19$61.92
52 Week Range$30.04 - $73.95$46.01 - $80.80
% from 52W High-5.08%-23.37%
All-Time High$220.20 (Jan 11, 2021)$135.96 (Sep 20, 2021)
% from All-Time High-68.12%-54.46%
Growth Metrics
Quarterly Revenue Growth0.73%0.04%
Quarterly Earnings GrowthN/A0.04%
Financial Health
Profit Margin (TTM) i-2.15%0.06%
Operating Margin (TTM) i-149.18%0.36%
Return on Equity (TTM) i-0.25%0.04%
Debt to Equity (MRQ) i12.5923.14
Cash & Liquidity
Book Value per Share (MRQ)$19.36$12.38
Cash per Share (MRQ)$18.93$1.04
Operating Cash Flow (TTM) i$-324,771,008$287.56M
Levered Free Cash Flow (TTM) i$-239,332,128$313.92M
Dividends
Last 12-Month Dividend Yield iN/A0.79%
Last 12-Month Dividend iN/A$0.40

Valuation & Enterprise Metrics Analysis: Crispr Therapeutics vs Bio-Techne

MetricCRSPTECH
Price Ratios
P/E Ratio (TTM) i-15.61136.85
Forward P/E i-13.4428.74
PEG Ratio i-0.26-0.96
Price to Sales (TTM) i161.928.04
Price to Book (MRQ) i3.505.08
Market Capitalization
Market Capitalization i$6.24B$9.80B
Enterprise Value i$4.66B$10.07B
Enterprise Value Metrics
Enterprise to Revenue i122.348.26
Enterprise to EBITDA i-10.6530.42
Risk & Other Metrics
Beta i1.841.48
Book Value per Share (MRQ) i$19.36$12.38

Financial Statements Comparison: Crispr Therapeutics vs Bio-Techne

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)CRSPTECH
Revenue/Sales i$0$316.96M
Cost of Goods Sold i$57.51M$118.15M
Gross Profit i$-57.51M$198.81M
Research & Development i$72.48M$26.03M
Operating Income (EBIT) i$-148.42M$116.69M
EBITDA i$-143.69M$6.43M
Pre-Tax Income i$-134.89M$-22.86M
Income Tax i$1.11M$-5.18M
Net Income (Profit) i$-136.00M$-17.68M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)CRSPTECH
Cash & Equivalents i$235.18M$162.19M
Total Current Assets i$1.87B$608.30M
Total Current Liabilities i$119.45M$175.85M
Long-Term Debt i$201.85M$429.96M
Total Shareholders Equity i$1.83B$1.92B
Retained Earnings i$-1.50B$1.07B
Property, Plant & Equipment i$182.48M$73.40M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)CRSPTECH
Operating Cash Flow i$-96.31M$7.55M
Capital Expenditures i$-206,000$-4.89M
Free Cash Flow i$-54.15M$93.31M
Debt Repayment iN/A$-50.00M
Common Stock Repurchase iN/A$-100.06M

Short Interest & Institutional Ownership Analysis

MetricCRSPTECH
Shares Short i23.81M5.27M
Short Ratio i12.642.59
Short % of Float i0.30%0.04%
Average Daily Volume (10 Day) i2,514,7393,192,556
Average Daily Volume (90 Day) i2,285,1102,630,039
Shares Outstanding i85.74M154.97M
Float Shares i90.51M153.71M
% Held by Insiders i0.02%0.00%
% Held by Institutions i0.81%1.04%

Dividend Analysis & Yield Comparison: Crispr Therapeutics vs Bio-Techne

MetricCRSPTECH
Last 12-Month Dividend iN/A$0.40
Last 12-Month Dividend Yield iN/A0.79%
3-Year Avg Annual Dividend iN/A$0.35
3-Year Avg Dividend Yield iN/A0.12%
3-Year Total Dividends iN/A$1.04
Ex-Dividend DateN/AAug 18, 2025